Lv11
70 积分 2023-08-17 加入
Physiologically based pharmacokinetic modeling of ponatinib to describe drug–drug interactions in patients with cancer
11天前
已完结
Advancements in physiologically based pharmacokinetic modeling for fedratinib: updating dose guidance in the presence of a dual inhibitor of CYP3A4 and CYP2C19
12天前
已完结
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
12天前
已完结
PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
12天前
已完结
Physiologically Based Pharmacokinetic Modeling of the Drug–Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study
13天前
已完结
Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors
13天前
已完结
Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers
13天前
已完结
Application of physiologically based pharmacokinetic modelling for the prediction of drug–drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes
13天前
已完结
Physiologically Based Pharmacokinetic Modeling of Midostaurin and Metabolites at Steady-state to Bridge Drug Interaction Scenarios In Lieu of Clinical Trials
13天前
已关闭
Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax
13天前
已完结
皖公网安备34019202002308
